IDO2 and non-small cell lung carcinoma: Moreover, we aim to unveil potential correlations between IDO2 expression, clinical-pathological parameters, immunosuppressive molecules of the tumor microenvironment and patients' prognosis, in order to outline IDO2 as both a potential new biomarker for better patient risk stratification and as a possible target for the pharmacological treatment of NSCLC.